The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Efficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Lopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Zhou, X., Liu, S., Kim, E. S., Herbst, R. S., & Lee, J. J. (2008) · Clinical Trials · doi:10.1177/1740774508091815 · Cited by 206
Clinical Approval Success Rates for Investigational Cancer Drugs
DiMasi, J. A., Reichert, J. M., Feldman, L., & Malins, A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.117 · Cited by 203
Lara, P. N., Redman, M. W., Kelly, K., Edelman, M. J., Williamson, S. K., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0344 · Cited by 182
Biomarker enrichment strategies: matching trial design to biomarker credentials
Freidlin, B., & Korn, E. L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.218 · Cited by 177
Seymour, L., Ivy, S. P., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M. J., Le Blanc, M., Stewart, D., Crowley, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3287 · Cited by 158
Self-citationDesigning Transformative Clinical Trials in the Cancer Genome Era
Sleijfer, S., Bogaerts, J., & Siu, L. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3639 · Cited by 156
Hyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P. J., Baselga, J. M., Berger, M. F., & Ladanyi, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.005 · Cited by 154
Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
Polley, M.-Y. C., Freidlin, B., Korn, E. L., Conley, B. A., Abrams, J. S., & McShane, L. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt282 · Cited by 151
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 150
Berry, D. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.011 · Cited by 150
Evaluating Many Treatments and Biomarkers in Oncology: A New Design
Kaplan, R. S., Maughan, T., Crook, A. M., Fisher, D. J., Wilson, R. H., Brown, L. C., & Parmar, M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7905 · Cited by 149
Board on Health Care Services (2010) · National Academies Press eBooks · doi:10.17226/12879 · Cited by 136
Research methods to change clinical practice for patients with rare cancers
Billingham, L. J., Malottki, K., & Steven, N. M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00396-4 · Cited by 118
Menis, J., Hasan, B., & Besse, B. (2014) · European Respiratory Review · doi:10.1183/09059180.00004214 · Cited by 113
The Bayesian basket design for genomic variant-driven phase II trials
Simon, R. M., Geyer, S. M., Subramanian, J., & Roychowdhury, S. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.01.002 · Cited by 99
Redman, M. W., & Allegra, C. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.07.009 · Cited by 91
Clinical trial designs incorporating predictive biomarkers
Renfro, L. A., Mallick, H., An, M., Sargent, D. J., & Mandrekar, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.008 · Cited by 85
Self-citationTourneau, C. L., Paolettí, X., Servant, N., Bièche, I., Gentien, D., Frio, T. R., Vincent‐Salomon, A., Servois, V., Roméjon, J., Mariani, O., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.211 · Cited by 78
The combinatorial complexity of cancer precision medicine
Klauschen, F., Andreeff, M., Keilholz, U., Dietel, M., & Stenzinger, A. (2014) · Oncoscience · doi:10.18632/oncoscience.66 · Cited by 77
Controlled multi-arm platform design using predictive probability
Hobbs, B. P., Chen, N., & Lee, J. J. (2016) · Statistical Methods in Medical Research · doi:10.1177/0962280215620696 · Cited by 77
Precision oncology: A new era of cancer clinical trials
Renfro, L. A., An, M., & Mandrekar, S. J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.015 · Cited by 76
Self-citationImproving Clinical Trial Efficiency: Thinking outside the Box
Mandrekar, S. J., Dahlberg, S. E., & Simon, R. M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e141 · Cited by 75
An overview of the design and conduct of the BATTLE trials.
Liu, S., & Lee, J. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.07 · Cited by 69
Phase III Clinical Trial Development: A Process of Chutes and Ladders
Dilts, D. M., Cheng, S. K., Crites, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1273 · Cited by 67
An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do, K. T., Coyne, G. O., & Chen, A. P. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.08.01 · Cited by 61
Why Do Phase III Clinical Trials in Oncology Fail so Often?
Amiri‐Kordestani, L., & Fojo, T. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs180 · Cited by 58
ALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer
Gerber, D. E., Oxnard, G., & Govindan, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.91 · Cited by 54
Burock, S., Meunier, F., & Lacombe, D. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.016 · Cited by 51
Lung-MAP--framework, overview, and design principles.
Ferrarotto, R., Redman, M. W., Gandara, D. R., Herbst, R. S., & Papadimitrakopoulou, V. A. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.09.02 · Cited by 32
Malik, S. M., Pazdur, R., Abrams, J. S., Socinski, M. A., Sause, W. T., Harpole, D. H., Welch, J. J., Korn, E. L., Ullmann, C. D., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000314 · Cited by 24
Marchenko, O., Fedorov, V. V., Lee, J. J., Nolan, C., & Pinheiro, J. C. (2013) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479013513889 · Cited by 20
Is the NCI MATCH trial a match for gynecologic oncology?
Moore, K. N., & Mannel, R. S. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.003 · Cited by 19
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership
Chen, A., Conley, B., Hamilton, S. R., Williams, M., O'Dwyer, P., Arteaga, C., Gray, R., McShane, L. M., Li, S., Rubinstein, L., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)33006-4 · Cited by 16
Basket Trials: Just the End of the First Quarter
Stenzinger, A., Weichert, W., Lennerz, J. K., & Klauschen, F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1516 · Cited by 13
The changing world of oncology drug development-A global pharmaceutical company's perspective.
Galbraith, S. M. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.11 · Cited by 9
Cited by
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Park, J. J. H., Siden, E., Zoratti, M. J., Dron, L., Harari, O., Singer, J., Lester, R. T., Thorlund, K., & Mills, E. J. (2019) · Trials · doi:10.1186/s13063-019-3664-1 · Cited by 441
Marques, L., Costa, B., Pereira, M., Silva, A., Santos, J., Saldanha, L., Silva, I., Magalhães, P., Schmidt, S., & Vale, N. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030332 · Cited by 390
Metadata
- Authors
- Renfro, L. A., & Sargent, D. J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 28
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2531712550
- Cited by
- 271
- References
- 63
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.